Developing a new vaccine for Crimean-Congo hemorrhagic fever
Analysis of a novel Crimean-Congo hemorrhagic fever vaccine and its mechanism of protection in rodent models
This study is working on a new vaccine to help protect people from Crimean-Congo hemorrhagic fever, a serious illness, by testing different ways to boost the immune response using modified viruses, so we can find a safer and better option for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10894731 on NIH RePORTER |
What this research studies
This research focuses on creating a novel vaccine for Crimean-Congo hemorrhagic fever (CCHF), a severe viral disease with high fatality rates. The approach involves using inactivated rabies and vesicular stomatitis viruses as vectors to induce immunity against CCHF. The researchers will compare the effectiveness of these vaccine candidates in rodent models and establish a safe testing system to understand how the vaccine protects against the virus. This work aims to provide a safer and more effective vaccine option for a disease that poses significant public health risks.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research would be individuals living in or traveling to regions where Crimean-Congo hemorrhagic fever is endemic.
Not a fit: Patients who are not at risk of exposure to Crimean-Congo hemorrhagic fever, such as those living in non-endemic areas, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safe and effective vaccine that significantly reduces the risk of Crimean-Congo hemorrhagic fever in humans.
How similar studies have performed: While the approach of using inactivated rhabdoviral vectors is novel for CCHF, similar strategies have shown success in developing vaccines for other hemorrhagic fever viruses.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Schnell, Matthias Johannes — Thomas Jefferson University
- Study coordinator: Schnell, Matthias Johannes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.